Preinfection laboratory parameters may predict COVID-19 severity in tumor patients.

Alexander Kiani Romina RoeschClemens M WendtnerFrank KullmannThomas KubinThomas SüdhoffMarinela AugustinMarkus SchaichClemens Müller-NaendrupGerald IllerhausFrank HartmannHolger HebartRuth Seggewiss-BernhardtMartin BentzErnst Späth-SchwalbePeter ReimerUlrich KaiserMarkus KappUllrich GraevenJens-Marcus ChemnitzJörg BaeseckeHelmut LambertzRalph Naumann

Published in: Cancer medicine (2021)

The course of COVID-19 in patients with tumor diseases is highly variable. Preinfection laboratory parameters may aid to identify patients at risk for severe COVID-19 at an early stage prior to infection with the virus. German Clinical Trials Register identification: DRKS00023012.

Keyphrases

coronavirus disease
end stage renal disease
sars cov
early stage
clinical trial
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
randomized controlled trial
early onset
radiation therapy
phase ii